Onconetix, Inc. - ONCO Forward P/S Multiple

Public company logo of Onconetix (ONCO)

Onconetix, Inc. focuses on developing advanced diagnostic systems and pharmaceuticals for the therapy of urological tumors. The forward P/S indicator visualizes market expectations, where 1.90 serves as the base value of the parameter. The brand's ecosystem integrates biotechnology with telemedicine for men's health, while optimized raw material supply chains ensure stable procurement without logistical disruptions.

ONCO Onconetix: Market Cap to Future Revenue Ratio in the range 04/13/2024 - 11/15/2026

ONCO (Onconetix): analytical breakdowns and indicator data

- market price and analyst price targets:
General company analysis:Onconetix Corporation ONCO
Product sample of onconetix.gcs-web.com

Driven by patent protection and the scalability of its oncology drugs, Onconetix, Inc. (ONCO) is capable of increasing revenue without a proportional rise in costs, which is reflected in the trend of the expected P/S ratio. This indicator correlates market capitalization with projected sales, allowing investors to determine the extent of the premium paid for future growth and identify the boundaries of a fair business valuation during periods of expansion.

Analysis of competing companies

Forward P/S Multiple A (agilent.com)|Quest Corp (DGX) - Market Cap to Future Revenue Ratio|ILMN - Price-to-Projected Revenue Ratio|EXAS - Forward P/S Multiple|RVTY (Revvity) - Forward Price-to-Revenue Multiple|Bio-Rad - Forward Price to Sales|Price-to-Projected Revenue Ratio anbio.com|Forward P/S Multiple Sotera Health Company|Price-to-Projected Revenue Ratio QuidelOrtho (QDEL)|OPK - Market Cap to Future Revenue Ratio|caredx.com - Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Maravai LifeSciences Corp (MRVI)|FLGT: Forward Price-to-Revenue Multiple|Forward Price to Sales LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Price-to-Projected Revenue Ratio|OSUR: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple XGN|MDXH: Forward Price to Sales|Price-to-Projected Revenue Ratio Lucid Diagnostics Inc. (LUCD)|Price-to-Projected Revenue Ratio PRE (Prenetics Global Limited)|Forward P/S Multiple IMDX (Insight Molecular Diagnostics Inc)|Price to Expected Revenue Ratio TRIB (Trinity Biotech Corp)|PRPH - Price-to-Projected Revenue Ratio|Ainos (AIMD) - Forward Price-to-Revenue Multiple|CoDx (CODX) - Price-to-Projected Revenue Ratio|HSCS (Heart Test Labs) - Price-to-Projected Revenue Ratio|BMRA (Biomerica, Inc.) - Forward P/S Multiple|CDIO (Cardio Diagnostics) - Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Virax Biolabs (VRAX)|Price to Expected Revenue Ratio BJDX|Price-to-Projected Revenue Ratio Vermillion AWH|Accelerate Diagnostics Inc (AXDX) - Market Cap to Future Revenue Ratio|centogene.com - Forward P/S Multiple|ENZ (Enzo Biochem Inc.) - Market Cap to Projected Revenue|Market Cap to Future Revenue Ratio FRES|Market Cap to Future Revenue Ratio GTG Labs (GENE)|ME (23andme.com) - Forward P/S Multiple|Forward P/S Multiple Psychemedics Inc